Genetic complexity of diagnostically unresolved Ehlers-Danlos syndrome.

Alison Meynert, F Michael Pope, Marion Bartlett, Carole Cummings, Rodney Grahame, Hanadi Kazkaz, Daniel J Toddie-Moore, David A Parry, Ruwan A Weerakkody, Timothy J Aitman, Angela F Brady, Jana Vandrovcova, Heather J Cordell, Anthony M Vandersteen, Fleur S van Dijk, Javier Santoyo-Lopez, Rebecca Darlay, Christina Kanonidou, Neeti Ghali

Journal: Journal of medical genetics 2024;61(3):232-238

PMID: 37813462

Abstract

BACKGROUND

The Ehlers-Danlos syndromes (EDS) are heritable disorders of connective tissue (HDCT), reclassified in the 2017 nosology into 13 subtypes. The genetic basis for hypermobile Ehlers-Danlos syndrome (hEDS) remains unknown.

METHODS

Whole exome sequencing (WES) was undertaken on 174 EDS patients recruited from a national diagnostic service for complex EDS and a specialist clinic for hEDS. Patients had already undergone expert phenotyping, laboratory investigation and gene sequencing, but were without a genetic diagnosis. Filtered WES data were reviewed for genes underlying Mendelian disorders and loci reported in EDS linkage, transcriptome and genome-wide association studies (GWAS). A genetic burden analysis (Minor Allele Frequency (MAF) <0.05) incorporating 248 Avon Longitudinal Study of Parents and Children (ALSPAC) controls sequenced as part of the UK10K study was undertaken using TASER methodology.

RESULTS

Heterozygous pathogenic (P) or likely pathogenic (LP) variants were identified in known EDS and Loeys-Dietz (LDS) genes. Multiple variants of uncertain significance where segregation and functional analysis may enable reclassification were found in genes associated with EDS, LDS, heritable thoracic aortic disease (HTAD), Mendelian disorders with EDS symptomatology and syndromes with EDS-like features. Genetic burden analysis revealed a number of novel loci, although none reached the threshold for genome-wide significance. Variants with biological plausibility were found in genes and pathways not currently associated with EDS or HTAD.

CONCLUSIONS

We demonstrate the clinical utility of large panel-based sequencing and WES for patients with complex EDS in distinguishing rare EDS subtypes, LDS and related syndromes. Although many of the P and LP variants reported in this cohort would be identified with current panel testing, they were not at the time of this study, highlighting the use of extended panels and WES as a clinical tool for complex EDS. Our results are consistent with the complex genetic architecture of EDS and suggest a number of novel hEDS and HTAD candidate genes and pathways.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Address: Maritime Medical Genetics Service, IWK Health Centre, Halifax, Nova Scotia, Canada [email protected] [email protected].; Faculty of Medicine, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; Institute of Clinical Sciences, Imperial College London, London, UK.; Department of Vascular Surgery, Royal Free Hospital, London, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.; Department of Clinical Biochemistry, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK.; Department of Neuromuscular Diseases, UCL Queen Street Institute of Neurology, University College London, London, UK.; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.; Edinburgh Genomics, University of Edinburgh, Edinburgh, UK.; MRC Human Genetics Unit, University of Edinburgh, Edinburgh, UK.; Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK.; Ehlers-Danlos Syndrome National Diagnostic Service, London North West University Healthcare NHS Trust, Northwick Park Hospital, Harrow, UK.; Department of Metabolism, Digestion and Reproduction Section of Genetics and Genomics, Imperial College London, London, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK [email protected] [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.